Showing 3 posts of 3 posts found.


NICE rejects Roche’s Polivy combo in relapsed or refractory diffuse large B-cell lymphoma

February 26, 2020
Manufacturing and Production, Research and Development, Sales and Marketing NHS, NICE, Polivy, Roche

It has been revealed that UK drug watchdog NICE has chosen to reject Roche’s Polivy (polatuzumab vedotin), used alongside rituximab …


EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

January 21, 2020
Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed.

Roche scores FDA approval for Polivy combo in diffuse large B-cell lymphoma

June 11, 2019
Manufacturing and Production, Sales and Marketing Polivy, Roche, lymphoma, pharma

Roche is celebrating the decision taken by the FDA to approve its anti-CD79b antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) in combination …

Latest content